Low Dose Naltrexone for Treatment of Multiple Sclerosis
- 1 October 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 35 (5) , 609-611
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factorBrain Research Bulletin, 2013
- A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosisJournal of Clinical Pharmacy and Therapeutics, 2013
- Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitisBrain Research, 2012
- The opioid growth factor–opioid growth factor receptor axis: Homeostatic regulator of cell proliferation and its implications for health and diseaseBiochemical Pharmacology, 2012
- Immunotherapies in Neurologic DisordersMedical Clinics of North America, 2012
- New treatments and treatment goals for patients with relapsing-remitting multiple sclerosisCurrent Opinion in Neurology, 2012
- Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosisBrain Research, 2011
- The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trialMultiple Sclerosis Journal, 2010
- Critical role of preproenkephalin in experimental autoimmune encephalomyelitisJournal of Neuroimmunology, 2006
- Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: A role for endogenous opioid systems in cancerLife Sciences, 1984